Immunotherapy Using Autoclaved L. major Antigens and M. vaccae with Meglumine Antimoniate, for the Treatment of Experimental Canine Visceral Leishmaniasis
,
Abstract
Background: To evaluate immunotherapy against canine visceral leishmaniasis, Leishmania major antigen and heat-killed Mycobacterium vaccae (SRL172) were used as stimulators of immune defense mechanisms and the results were compared with standard chemotherapy meglumine antimoniate.
Methods: Nineteen mongrel dogs aging 1-3 years old were used in this experiment. Infection was carried out in 15 out of 19 dogs using L. infantum, isolated from a naturally infected poly-symptomatic dog.
Results: All the cases showed positive serologic results by direct agglutination test during 30-60 days following inoculation. In the first group, which was under chemotherapy (GlucantimeR), one of the members showed recurrence of the disease despite rapid effect of the therapeutic protocol. Immunotherapy using SRL172 caused complete cleaning of the parasite in group 2, but the speed was less than Glucantime. Immunotherapy using L. major antigen combined with M. vaccae in group 3 and combine administration of immunotherapy and chemotherapy in group 4 both were with relapsing of one case in each group. Group 5 and 6 were consisted of positive and negative control dogs, respectively.
Conclusion: Immunotherapy seems to be an adjuvant in treatment of canine leishmaniasis but it needs more investigation for final confirmation.
Slappendel RJ, Ferrer L. Leishmaniasis. In:GreeneCE, editor. Infectious diseases of the dog and cat. Philadelphia: WB SaundersCo.;2005. p. 685-698.
Mohebali M, Hajjaran H, Hamzavi Y, Mobedi I, Arshi S, Zarei Z,AkhoundiB, Naeini KM, Avizeh R, Fakhar M. Epidemiological aspects of canine visceral leishmaniasis in the Islamic Republic of Iran. Vet Parasitol. 2005; 129(3- 4):243-51.
Coukell AJ, Brogden RN. Liposomal amphotericin B: Therapeutic use in the management of fungal infections and visceral leishmaniosis. Drugs. 1998; 55(4):585-612.
OlivaG, Gradoni L, Cortese L,Orsini S, Ciaramella P, Scalone A, de Luna R, Perechino A. Comparative efficacy of meglumine antimoniate and aminosidine sulphate, alone or in combination, in canine leishmaniosis. Ann Trop Med Parasitol. 1998; 92(2):165-71.
Chapman WL Jr, Hanson WL, Alving CR, Hendricks LD. Antileishmanial activity of liposome-encapsulated meglumine antimonate in the dog. AmJ VetRes. 1984;45(5):1028-30.
Murray HW. Effect of continuous administration of interferon-gamma in experimental visceral leishmaniasis. J InfectDis. 1990;161(5):992-4.
MohebaliM, Parsa B,MotazedianMH, Yaghoobi-Ershadi MR, Hajjaran H. Identification of Leishmania species from different parts of Iran using a random amplified polymorphic DNA in human, animal reservoirs and vectors. Med J Islamic Rep Irn. 2002; 15(2):243–6.
Edrissian GhH, Hajaran H, MohebaliM, Soleiman Zadeh G, Bokaei S, Anvari A, Sarkissian MT, Kanani A, Nadim A. Application and evaluation of direct agglutination test in sero–diagnosis of visceral leishmaniasis in man and canine reservoirs in Iran. Iran J Med Sci. 1996; 21(2):119-24.
Mohebali M, Taran M, Zarei Z. Rapid detection of Leishmania infantum infection in dogs: Comparative study using immunochromatographic dipstick rK39 test and direct agglutination. Vet Parasitol. 2004; 121(3-4):239-45.
Abranches P, Santos-Gomes G, Rachamim N, Campino L, Schnur LF, Jaffe CL. An experimental model for canine visceral leishmaniasis. Parasite Immunol. 1991;13(5):537-50.
Bergeaud P. The contribution of corticotherapy in the treatment of certain forms of canine leishmaniosis: results of a series of forty-three cases. Prat Med Chirurg AnimComp. 1988;23(5):121-7.
Melo MA, Franca-Silva JC, Azevedo EO, Costa RTDA, Costa CADA, Costa JO,Mayrink W,GenaroO. Treatment of canine visceral leishmaniosis with glucantime plus immunotherapy. Mem InstOswaldoCruz. 1996;91:44.
Neogy AB, Vouldoukis I, da Costa JM, Monjour L. Exploitation of parasite-derived antigen in therapeutic success against canine visceral leishmaniosis. VetParasitol. 1994;54(4):367-73.
Mayo REP, Stanford JL. Double blind placebo-controlled trial of Mycobacterium vaccae immunotherapy for tuberculosis in KwaZulu, South Africa, 1991-97. Trans R Soc Trop Med Hyg. 2000;94(5):563-8.
Balagon MV, Walsh DS, Tan PL, Cellona RV, Abalos RM, Tan EV, Fajardo TT, Watson JD, Walsh GP. Improvement in psoriasis after intradermal administration of heat-killedMycobacterium vaccae. Int J Dermatol. 2000; 39(1):51-8.
Breivik T, Rook GAW. Prevaccination with SRL172 (heat-killed Mycobacteriumvaccae) inhibits experimental periodontal disease in Wistar rats. Clin Exp Immunol. 2000;120(3):463-7.
Wang CC, Rook GA. Inhibition of an established allergic response to ovalbumin in BALB/c mice by killed Mycobacterium vaccae. Immunology. 1998;93(3):307-13.
Sharifi I, Fekri AR, Aflatonian MR, Khamesipour A, Nadim A, Mousavi MR, Momeni AZ, Dowlati Y, Godal T, Zicker F, Smith PG, Modabber F. Randomised vaccine trial of single dose of killed leishmania major plus BCG against anthroponothic cuthaneous leishmaniasis in Bam, Iran. Lancet. 1998;351(9115):1540-3.
Pinelli E, Rutten VP, Bruysters M, Moore PF, Ruitenberg EJ. Compensation for decreased expression of B7 molecules on Leishmania infantum-infected canine macrophages results in restoration of parasite-specific T-cell proliferation and gamma interferon production. Infect Immun. 1999;67(1):237-43. 20. Cabrera M, Blackwell JM, Castes M, Trujillo D, Convit J, Shaw MA. Immunotherapywith live BCGplus heat killed Leishmania induces a T helper 1- like response in American cutaneous leishmaniasis patients. Parasite Immunol. 2000;22(2):73-9.
Skeiky YA, Kennedy M, Kaufman D, Borges MM, Guderian JA, Scholler JK, Ovendale PJ, Picha KS, Morrissey PJ, Grabstein KH, Campos-Neto A, Reed SG. LeIF: a recombinant Leishmania protein that induces an IL-12-mediated Th1 cytokine profile. J Immunol. 1998; 161(11):6171-9.
Sjolander A, Baldwin TM, Curtis JM, BengtssonKL,Handman E. Vaccination with recombinant parasite surface antigen 2 from Leishmania major induces a Th1 type of immune response but does not protect against infection. Vaccine. 1998;16(20):2077-84.
Everlien H, Hockertz S. Combined liposomal immuno and chemotherapy of visceral leishmaniasis. Arzneimittelforschung. 1999;49(11):954-61.
Van Lunzen J, Kern P, Schmitz J, Brzoska J, Flessenkamper S, DietrichM. Short term treatment of visceral leishmaniasis of the old world with low dose interferon gamma and pentavalent antimony. Infection. 1993;21(6):362-6.
Melo MA, Franca-Silva JC, Azevedo EO, da Costa RT, da Costa CA, Toledo VPCP, Costa JO, Mayrink W, Genaro O. Therapeutic clinical trial for asymptomatic canine visceral leishmaniosis by the use of glucantime in association with immunotherapy. Mem Inst Oswaldo Cruz. 1996;91:290.
| Files | ||
| Issue | Vol 6 No 3 (2011) | |
| Section | Articles | |
| Keywords | ||
| Canine visceral leishmaniasis Immunotherapy Glucantime Mycobacterium vaccae | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
